Biodesy, Inc. Enters into Research Collaboration with Amgen

Biodesy, Inc. announced today that it has entered into a research collaboration agreement with Amgen Inc. (Thousand Oaks, Calif.) to support Amgen’s neuroscience drug discovery programs. Biodesy will apply its proprietary technology to screen and characterize novel chemical matter against a clinically relevant target, based on direct, real-time measurements of the structural changes induced by associated molecular interactions. Under the terms of the agreement, Biodesy is eligible to receive compensation for assay development and for screening Amgen’s fragment library.

Biodesy Inc. Completes $15.0 Million Series A Financing and Appoints Greg Yap as Chief Executive Officer

Biodesy, Inc., a privately held developer of novel systems to analyze real-time protein function for research and clinical applications, announced today that it has closed a $15.0 million Series A venture financing round from 5AM Ventures, Pfizer Venture Investments and Roche Venture Fund. In addition, Greg Yap has been named Chief Executive Officer and a Director.


SLAS 2016

January 23 - 27, 2016 San Diego, CA, USA